Atara Biotherapeutics, Inc.
$7.71 -$0.19 (-2.41%) 1D Market openKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 24
An insider transaction hit the record.
Form 4s are events, not verdicts — officers, directors, and 10% owners reporting their own trades. The forms post hours before the media writes them up.
RECEIPT: SEC FORM 4, TIMESTAMPED -
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
May 7
The stock moved +92.8% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, May 7 -
Mar 30
From its Mar 12 high, the share price fell 37%.
Peak close $6.90 on Mar 12; trough close $4.32 on Mar 30. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -37% -
Mar 9
The stock moved +29.2% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Mar 9
The story updates itself as events post · The wolf reports; you decide
Snapshot
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.